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OBJECTIVES: The purpose of this study was to compare the
cost of the oral therapy with capecitabine + IV cisplatin (XP)
against standard IV therapy with 5-ﬂuoruracil + cisplatin (FP) as
ﬁrst-line treatment for patients with advanced gastric cancer
(AGC). METHODS: A cost minimization analysis was con-
ducted based on clinical data from the phase III trial of Kang
et al. 2006. In this trial patients were treated until disease pro-
gression, which corresponded to 5.22 cycles of chemotherapy for
XP and 4.56 cycles for FP (Kang et al. 2006). Progression free-
survival and overall survival with XP was non-inferior to FP.
Therefore, we assumed that both treatments compared in this
study had the same effectiveness. We considered direct costs
(drugs, administration of drug, physician fees), non-medical
direct costs per patient (transportation to hospital) and indirect
costs (hours of absence from work). A Delphi panel was con-
ducted to identify local practices and resources use in Brazil.
Costs such as medical payment, pre and post medication and
administration were also included. One-way and multi-way sen-
sitivity analyses were performed for testing robustness of results.
RESULTS: Total cost per patient in the XP group (R$14,247)
was signiﬁcantly lower than the total cost per patient in the FP
group (R$15,649). As a result of the additional visits for infusion
of 5-FU, FP patients incurred greater indirect costs in terms of
lost time. The sensitivity analysis conﬁrmed the robustness of the
results. Capecitabine beneﬁts AGC patients by reducing the
number of infusion visits and time spent receiving IV adminis-
tration, and would produce signiﬁcant direct medical cost
savings. CONCLUSION: Findings of this cost-minimization
analysis suggest XP as a cost-saving alternative from the Brazil-
ian societal perspective.
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OBJECTIVES: To perform a cost-minimisation and budget
impact analysis of erlotinib versus docetaxel or pemetrexed for
the treatment of patients with advanced NSCLC who have failed
previous chemotherapy. METHODS: In the absence of head-
to-head clinical trial data for erlotinib versus docetaxel or
pemetrexed, equivalent efﬁcacy was assumed for the three inter-
ventions; indirect comparisons of phase III trial results suggest
that this was a conservative assumption. We developed a cost-
minimisation and budget impact model for cost comparison of
these three treatments based on the results of the BR.21 study of
erlotinib, and pivotal trials for docetaxel and pemetrexed, adopt-
ing a Brazilian private payer perspective. A 126-day timeframe
was used for the comparison, based on the progression-free
survival observed in the BR.21 study. A Delphi panel was con-
ducted to identify local practices and their associated costs in
Brazil. Other costs such as medical payment, pre- and post-
medication, and administration were also included. One-way
and multi-way sensitivity analyses were performed to assess the
robustness of the outcomes. Discounting was not included due to
the short-term perspective of the analysis. RESULTS: Total costs
were R$26,825 for erlotinib, R$42,284 for docetaxel and
R$79,841 for pemetrexed. The cost-savings observed for erlo-
tinib were due to lower acquisition costs (R$26,795 versus
R$40,217 for docetaxel and R$78,911 for pemetrexed) and its
more favourable tolerability proﬁle. Sensitivity analyses con-
ﬁrmed the robustness of the results obtained. The budget impact
analysis showed savings in the ﬁrst year after incorporation of
erlotinib starting from R$3,576,931 in a conservative scenario,
and reaching R$32,192,379 at the upper limit. CONCLUSION:
The ﬁndings of this cost-minimisation analysis suggest that erlo-
tinib is a cost-saving alternative under the private health care
system perspective in Brazil.
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OBJECTIVES: A cost-minization analysis compared costs and
medical resources of the treatment of pegﬁlgastrim (PF) versus
ﬁlgastrim (F), for the prophylaxis of chemotherapy (CT)-induced
febrile neutropenia (FN) in high-risk stage II-IV breast cancer
patients. METHODS: Two important clinical trials compared
the efﬁcacy of pegﬁlgrastim versus ﬁlgrastim: Holmes et al. 2002
and Green et al. 2003. Those studies have shown that a single
dose of pegﬁlgrastim corresponds, in terms of severe neutropenia
time reduction, to approximately 11 doses of ﬁlgrastim. Data of
FN incidence was provided by a retrospective study based on a
phase III trial (Green et al. 2002). According to that study, peg-
ﬁlgastrim arm was more effective to decrease the FN incidence,
consequently, hospitalization (PF 18% vs. F 31%), blood trans-
fusion (PF 4% vs. F 25%) and IV antibiotics (PF 17% vs. F
21%). For the base case a patient with 72.8 Kg was considered.
A panel with Brazilian experts was conducted to determine local
practice for prophylaxis of FN and in the treatment of patients
who develop FN. Only direct costs were considered: drugs
administration, hemograms, daily hospital costs, transfusion and
antibiotics costs. As per clinical trials the time horizon considered
was 4 months therefore discounting was not applied. This assess-
ment was undertaken from the Brazilian payer perspective.
RESULTS: Acquisition drug costs for pegﬁlgastrim were higher
than ﬁlgastrim (R$ 5010 vs. R$ 447). However, pegﬁlgastrim
treatment was cost-saving (R$ 4631) due to the reduction in the
number of administrations per CT cycle (1 vs. 11). One-way
sensitivity analysis was conducted and results were robust. CON-
CLUSION: Findings suggest pegﬁlgastrim as a cost-saving
therapy for the prophylaxis of CT-induced FN under the payer
perspective in Brazil.
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OBJECTIVES: A cost minimization analysis was developed to
compare the costs of intra-venous biphosphonates therapies
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